130 Chapter 3 plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve 2016; 53(6): 872-6. 22. Gelinas D, Katz J, Nisbet P, England JD. Current practice patterns in CIDP: A cross-sectional survey of neurologists in the United States. J Neurol Sci 2019; 397: 84-91. 23. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. The Lancet Neurology 2008; 7(2): 136-44. 24. Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci 2014; 35(7): 1023-34. 25. Le Masson G, Sole G, Desnuelle C, et al. Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis. Brain Behav 2018; 8(2): e00923. 26. Maheshwari A, Sharma RR, Prinja S, et al. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin. J Clin Apher 2018; 33(6): 631-7. 27. Meyer A, Scire CA, Talarico R, et al. Idiopathic inflammatory myopathies: narrative review of unmet needs in clinical practice guidelines. RMD open 2018; 4(Suppl 1): e000784. 28. O’Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Frontiers in neurology 2020; 11: 743. 29. Press R, Hiew FL, Rajabally YA. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. Acta Neurol Scand 2016; 133(4): 228-38. 30. Rajabally YA. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. Journal of neurology, neurosurgery, and psychiatry 2014; 85(6): 631-7. 31. Sanders DB, Wolfe GI, Narayanaswami P. Developing treatment guidelines for myasthenia gravis. Annals of the New York Academy of Sciences 2018; 1412(1): 95-101. 32. Stangel M, Gold R, Pittrow D, et al. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord 2016; 9(3): 165-79. 33. Tsai CP. Pharmacoeconomics of intravenous immunoglobulin in various neurological disorders. Acta Neurol Taiwan 2010; 19(4): 303-8. 34. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology 2018; 17(1): 35-46. 35. Verboon C, Doets AY, Galassi G, et al. Current treatment practice of Guillain-Barré syndrome. Neurology 2019; 93(1): e59-e76. 36. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C, Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC health services research 2011; 11: 101. 37. Yokoyama K, Hattori N. Management of myasthenia gravis in daily practice for general neurologists and healthcare professionals. Clinical and Experimental Neuroimmunology 2017; 8(2): 162-70. 38. Sung N, Han AR, Park CW, et al. Intravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines. Clin Exp Reprod Med 2017; 44(1): 1-7. 39. Shaulov T, Sierra S, Sylvestre C. Recurrent implantation failure in IVF: A Canadian Fertility and Andrology Society Clinical Practice Guideline. Reprod Biomed Online 2020; 41(5): 819-33. 40. Callec R, Unlu O, Olivier M, Denis W, Stephane Z. Effectiveness of treatment in the secondary prevention of obstetric complications in the antiphospholipid syndrome: Systematic review and meta-analysis. Human Reproduction 2016; Conference(Supplement 1): i31. 41. Okubo Y, Michihata N, Morisaki N, et al. Recent trends in practice patterns and comparisons between immunoglobulin and corticosteroid in pediatric immune thrombocytopenia. Int J Hematol 2018; 107(1): 75-82. 42. Wegnelius G, Bremme K, Lindqvist PG. Efficacy of treatment immune thrombocytopenic purpura in pregnancy with corticosteroids and intravenous immunoglobulin: a prospective follow-up of suggested practice. Blood Coagul Fibrinolysis 2018; 29(2): 141-7. 43. Colla L, Diena D, Rossetti M, et al. Immunosuppression in pregnant women with renal disease: review of the
RkJQdWJsaXNoZXIy MTk4NDMw